Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

124.78
BATS BZX Real-Time Price
As of 10:49am ET
 +0.26 / +0.21%
Today’s Change
102.10
Today|||52-Week Range
149.34
+4.34%
Year-to-Date
Alexion (ALXN) Submits Application for ALXN1210 with FDA
Jun 20 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
Jun 13 / Zacks.com - Paid Partner Content
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
Jun 20 / Zacks.com - Paid Partner Content
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
Jun 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close124.52
Today’s open124.07
Day’s range124.00 - 124.78
Volume20,962
Average volume (3 months)1,931,253
Market cap$27.3B
Data as of 10:49am ET, 06/21/2018

Growth & Valuation

Earnings growth (last year)+11.93%
Earnings growth (this year)+18.62%
Earnings growth (next 5 years)+15.70%
Revenue growth (last year)+17.32%
P/E ratio53.5
Price/Sales7.63
Price/Book3.07

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc-0.04-0.05%
BAXBaxter International...+0.18+0.25%
INCYIncyte Corp+0.60+0.82%
VRTXVertex Pharmaceutica...-1.74-1.10%
Data as of 10:49am ET, 06/21/2018

Financials

Next reporting dateJuly 26, 2018
EPS forecast (this quarter)$1.69
Annual revenue (last year)$3.5B
Annual profit (last year)$443.3M
Net profit margin12.55%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Ludwig N. Hantson
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
New Haven, Connecticut

Forecasts